Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-ARF
2024-512641-16-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary endotheliopathy and acute respiratory decompensation comparing Ilomedin with Placebo (2 arms). Primary endpoint: 28-day all-cause mortality. Planned start Mar 2024; status: authorised.
02
Drugs
iloprost
03
Conditions
Pulmonary endotheliopathyacute respiratory decompensation
Beyond the preview
Go deeper on 2024-512641-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512641-16-00.